Jeremy S. Abramson
Jeremy S. Abramson
Assistant Professor of Medicine, Harvard Medical School
Verified email at mgh.harvard.edu
Title
Cited by
Cited by
Year
OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines
W Zhang, RW Moskowitz, G Nuki, S Abramson, RD Altman, N Arden, ...
Osteoarthritis and cartilage 16 (2), 137-162, 2008
30592008
B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large …
M Snuderl, OK Kolman, YB Chen, JJ Hsu, AM Ackerman, P Dal Cin, ...
The American journal of surgical pathology 34 (3), 327, 2010
4042010
Non-Hodgkin’s lymphomas
AD Zelenetz, JS Abramson, RH Advani, CB Andreadis, JC Byrd, ...
Journal of the National Comprehensive Cancer Network 8 (3), 288-334, 2010
3732010
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis
AM Petrich, M Gandhi, B Jovanovic, JJ Castillo, S Rajguru, DT Yang, ...
Blood, The Journal of the American Society of Hematology 124 (15), 2354-2361, 2014
3312014
The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma
P Juszczynski, J Ouyang, S Monti, SJ Rodig, K Takeyama, J Abramson, ...
Proceedings of the National Academy of Sciences 104 (32), 13134-13139, 2007
3232007
Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL
JA Woyach, AS Ruppert, NA Heerema, W Zhao, AM Booth, W Ding, ...
New England Journal of Medicine, 2018
2982018
Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach
JS Abramson, MA Shipp
Blood 106 (4), 1164-1174, 2005
2322005
Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma
JS Abramson, M Hellmann, JA Barnes, P Hammerman, C Toomey, ...
Cancer 116 (18), 4283-4290, 2010
2032010
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
BL Lampson, SN Kasar, TR Matos, EA Morgan, L Rassenti, MS Davids, ...
Blood, The Journal of the American Society of Hematology 128 (2), 195-203, 2016
1932016
Evaluating the impact of the humanities in medical education
AW Schwartz, JS Abramson, I Wojnowich, R Accordino, EJ Ronan, ...
Mount Sinai Journal of Medicine: A Journal of Translational and Personalized …, 2009
1442009
Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)
SJ Rodig, JS Abramson, GS Pinkus, SP Treon, DM Dorfman, HY Dong, ...
Clinical Cancer Research 12 (23), 7174-7179, 2006
1432006
Diagnosis and management of Castleman disease
JD Soumerai, AR Sohani, JS Abramson
Cancer control 21 (4), 266-278, 2014
1422014
Non-Hodgkin’s lymphomas, version 4.2014
AD Zelenetz, LI Gordon, WG Wierda, JS Abramson, RH Advani, ...
Journal of the National Comprehensive Cancer Network 12 (9), 1282-1303, 2014
1382014
Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis
JA Barnes, AS Lacasce, Y Feng, CE Toomey, D Neuberg, JS Michaelson, ...
Annals of Oncology 22 (8), 1859-1864, 2011
1382011
Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma: CALGB/Alliance 50303
WH Wilson, J Sin-Ho, BN Pitcher, ED Hsi, J Friedberg, B Cheson, ...
Blood, The Journal of the American Society of Hematology 128 (22), 469-469, 2016
1122016
End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin’s lymphoma
JA Barnes, AS LaCasce, K Zukotynski, D Israel, Y Feng, D Neuberg, ...
Annals of oncology 22 (4), 910-915, 2011
1112011
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
A Younes, P Hilden, B Coiffier, A Hagenbeek, G Salles, W Wilson, ...
Annals of Oncology 28 (7), 1436-1447, 2017
1102017
Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.
JS Abramson, LI Gordon, ML Palomba, MA Lunning, JE Arnason, ...
Journal of clinical oncology 36 (15_suppl), 7505-7505, 2018
1042018
Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy
JS Abramson, T Feldman, AR Kroll-Desrosiers, LS Muffly, E Winer, ...
Annals of oncology 25 (11), 2211-2217, 2014
912014
T‐cell/histiocyte‐rich B‐cell lymphoma: biology, diagnosis, and management
JS Abramson
The Oncologist 11 (4), 384-392, 2006
862006
The system can't perform the operation now. Try again later.
Articles 1–20